Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Diseases of complement dysregulation-an overview.

Wong EKS, Kavanagh D.

Semin Immunopathol. 2018 Jan;40(1):49-64. doi: 10.1007/s00281-017-0663-8. Epub 2018 Jan 11. Review.

2.

Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ.

J Immunol. 2018 Apr 1;200(7):2464-2478. doi: 10.4049/jimmunol.1701695. Epub 2018 Mar 2.

PMID:
29500241
3.

Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Wong EK, Kavanagh D.

Transl Res. 2015 Feb;165(2):306-20. doi: 10.1016/j.trsl.2014.10.010. Epub 2014 Oct 20. Review.

PMID:
25468487
4.

Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD, Huang Y, Huang M, Brodsky RA.

Haematologica. 2017 Mar;102(3):466-475. doi: 10.3324/haematol.2016.153312. Epub 2016 Nov 3.

5.

Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.

Risitano AM, Marotta S.

Semin Immunol. 2016 Jun;28(3):223-40. doi: 10.1016/j.smim.2016.05.001. Epub 2016 Jun 23. Review.

PMID:
27346521
6.

Eculizumab in pregnancy: a narrative overview.

Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D.

J Nephrol. 2018 Aug 29. doi: 10.1007/s40620-018-0517-z. [Epub ahead of print] Review.

PMID:
30159857
7.

Modeling complement-driven diseases in transgenic mice: Values and limitations.

Ueda Y, Gullipalli D, Song WC.

Immunobiology. 2016 Oct;221(10):1080-90. doi: 10.1016/j.imbio.2016.06.007. Epub 2016 Jun 16. Review.

PMID:
27371974
8.
9.

Complement activation in diseases presenting with thrombotic microangiopathy.

Meri S.

Eur J Intern Med. 2013 Sep;24(6):496-502. doi: 10.1016/j.ejim.2013.05.009. Epub 2013 Jun 4. Review.

PMID:
23743117
10.

Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.

Sridharan M, Go RS, Willrich MAV.

J Immunol Methods. 2018 Oct;461:15-22. doi: 10.1016/j.jim.2018.07.006. Epub 2018 Jul 19. Review.

PMID:
30031798
11.

Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD.

Semin Hematol. 2018 Jul;55(3):167-175. doi: 10.1053/j.seminhematol.2018.02.002. Epub 2018 Feb 14. Review.

PMID:
30032754
12.

Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration.

Geerlings MJ, Volokhina EB, de Jong EK, van de Kar N, Pauper M, Hoyng CB, van den Heuvel LP, den Hollander AI.

Clin Genet. 2018 Oct;94(3-4):330-338. doi: 10.1111/cge.13392. Epub 2018 Jul 10.

PMID:
29888403
13.

Complement the hemostatic system: an intimate relationship.

Weitz IC.

Thromb Res. 2014 May;133 Suppl 2:S117-21. doi: 10.1016/S0049-3848(14)50020-5. Review.

PMID:
24862131
14.

Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation.

Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA.

Adv Clin Chem. 2016;77:1-75. doi: 10.1016/bs.acc.2016.06.001. Epub 2016 Jul 5. Review.

PMID:
27717414
15.

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.

Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E.

Clin J Am Soc Nephrol. 2009 Aug;4(8):1312-6. doi: 10.2215/CJN.01090209. Epub 2009 Jun 25.

16.

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, Ricci P, Alfinito F, Camera A, Gianfaldoni G, Amendola A, Boschetti C, Di Bona E, Fratellanza G, Barbano F, Rodeghiero F, Zanella A, Iori AP, Selleri C, Luzzatto L, Rotoli B.

Blood. 2009 Apr 23;113(17):4094-100. doi: 10.1182/blood-2008-11-189944. Epub 2009 Jan 29.

17.
18.

Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.

Vernon KA, Ruseva MM, Cook HT, Botto M, Malik TH, Pickering MC.

J Am Soc Nephrol. 2016 May;27(5):1334-42. doi: 10.1681/ASN.2015030295. Epub 2015 Sep 15.

19.

Complement in hemolytic anemia.

Brodsky RA.

Blood. 2015 Nov 26;126(22):2459-65. doi: 10.1182/blood-2015-06-640995. Epub 2015 Nov 18. Review.

20.

Treatment of C3 glomerulopathy with complement blockers.

Vivarelli M, Emma F.

Semin Thromb Hemost. 2014 Jun;40(4):472-7. doi: 10.1055/s-0034-1375299. Epub 2014 May 5. Review.

PMID:
24799307

Supplemental Content

Support Center